TG Therapeutics, Inc.
787 Seventh Avenue
48th Floor
New York
New York
10019
United States
Tel: 212-554-4484
Fax: 212-554-4531
Website: http://www.tgtherapeutics.com/
Email: ir@tgtxinc.com
402 articles about TG Therapeutics, Inc.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
5/26/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and two poster presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held June 1-4, 2022, in National Harbor, Maryland.
-
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET
5/20/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference taking place next week.
-
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
4/26/2022
TG Therapeutics, Inc., announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference, taking place on Thursday, April 28, 2022, at 12:30 PM ET.
-
Toxicities and concerning patient survival data sparked a U.S. Food and Drug Administration advisory committee to recommend shutting the door on single-arm clinical studies of PI3K inhibitors.
-
The U.S. FDA's Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.
-
TG Therapeutics voluntarily withdrew its pending BLA and supplemental NDA for its treatment dubbed U2 for adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
-
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
4/15/2022
Company to host conference call, Monday, April 18, 2022 at 8:30 AM ET.
-
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
4/6/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) was presented at the American Academy of Neurology Meeting.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
4/4/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented over the weekend at the American Academy of Neurology (AAN) annual meeting, held in Seattle, Washington.
-
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
-
The FDA has a full PDUFA calendar for the second half of March for New Drug Applications and Biologics License Applications. Here's a look.
-
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
3/10/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has set a date of April 22, 2022 for the previously announced meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the Biologics License Application (BLA)/supplemental New Drug Application.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
3/4/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and three poster presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 2 – 7, 2022, in Seattle, Washington.
-
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLLFDA sets updated PDUFA goal date of June 25, 2022
3/3/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date to June 25, 2022 for the Biologics License Application (BLA) and supplemental New Drug Application (sNDA) for ublituximab.
-
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET
3/1/2022
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2021, and recent company developments, along with a business outlook for 2022.
-
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2/25/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, including additional analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS).
-
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business UpdateConference call to be held Tuesday, March 1, 2022 at 8:30 AM ET
2/24/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 1, 2022 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2021 and provide a business outlook for 2022.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2/15/2022
TG Therapeutics, Inc. today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS).
-
After announcing that the FDA was investigating a possible death associated with its lymphoma drug Ukoniq (umbralisib), things are seemingly looking up for TG Therapeutics.